Free Articles, Free Web Content, Reprint Articles
Thursday, July 2, 2020
 
Free Articles, Free Web Content, Reprint ArticlesRegisterAll CategoriesTop AuthorsSubmit Article (Article Submission)ContactSubscribe Free Articles, Free Web Content, Reprint Articles
 

Global Target Protein Degradation Market Deep Analysis by 2019-2030

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.

Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:

Type of payment of licensing agreements

  • Upfront payments
  • Milestone payments

Type of protein degrader

  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

Therapeutic area

  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

Route of administration 

  • Oral
  • Intravenous
  • Other routes

Key geographical region

  • North America
  • Europe
  • Asia-Pacific

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

Get detailed Analysis: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Key Players

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Profiles
  6. Clinical Trial Analysis
  7. KOL Analysis
  8. Publication Analysis
  9. Funding and Investment Analysis
  10. Partnerships and Collaborations
  11. Market Sizing and Opportunity Analysis
  12. Executive Insights
  13. Concluding Remarks
  14. Appendix 1: Tabulated Data
  15. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

 

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR


Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com



Health
Business
Finance
Travel
Technology
Home Repair
Computers
Marketing
Autos
Family
Entertainment
Education
Law
Communication
Other
ECommerce
Sports
Home Business
Self Help
Internet
Partners


Page loaded in 0.286 seconds